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Varicella-zoster virus (VZV) establishes latency in human sensory and cranial nerve 
ganglia during primary infection (varicella) and the virus can reactivate and cause zoster 
after primary infection. The mechanism of how the virus establishes and maintains 
latency, and how it reactivates is poorly understood, largely due to the lack of robust 
models. We found that axonal infection of neurons derived from human embryonic stem 
cells in a microfluidic device with cell-free parental Oka (POka) VZV resulted in latent 
infection with inability to detect several viral mRNAs by reverse transcriptase-
quantitative PCR, no production of infectious virus, and maintenance of the viral DNA 
genome in endless configuration, consistent with an episome configuration.  With deep 
sequencing, however, multiple viral mRNAs were detected. Treatment of the latently 
infected neurons with antibody to nerve growth factor (NGF) resulted in production of 
infectious virus in about 25% of the latently infected cultures. Axonal infection of 
neurons with vaccine Oka (VOka) VZV resulted in a latent infection similar to infection 
with POka, however, in contrast to POka, VOka-infected neurons were markedly 
impaired for reactivation after treatment with antibody to NGF. In addition, viral 
transcription was markedly reduced in neurons latently infected with VOka compared 
with POka. Our in vitro system recapitulates both VZV latency and reactivation in vivo 
and may be used to study viral vaccines for their ability to establish latency and 
reactivate.   
 
Significance 
The varicella vaccine is highly effective in preventing chickenpox. While the vaccine 
virus is attenuated, it is unknown whether the virus is impaired for establishment of 
latency, for reactivation, or both. We developed an in vitro system using human neurons 
derived from embryonic stem cells and showed that axonal infection of neurons results in 
latent infection and that virus can be reactivated using antibody to nerve growth factor. 
Using this system, we show that the varicella vaccine is impaired for reactivation, but not 
latency. Although not necessarily equivalent to VZV latency and reactivation in vivo, this 
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system may be used to study the ability of other viruses, including viral vaccines, to 
establish latency and reactivate.  \body 
 
INTRODUCTION 
Varicella-zoster virus (VZV) is a member of Alphaherpesvirinae, characterized by 
neurotropism and lifelong latent infection in human dorsal root, cranial nerve, and enteric 
ganglia (1). During primary infection (varicella), VZV gains access to sensory neurons by 
two potential routes: retrograde axonal transport from cutaneous lesions or infection of 
neurons by virus-infected T cells circulating through the body (2). The virus then 
establishes latency in neurons and months to years later, when VZV-specific T cells 
decline, the virus can reactivate to cause herpes zoster. 
VZV is only the human herpesvirus for which a licensed vaccine is approved and 
the live attenuated vaccine Oka (VOka) is effective in preventing both varicella and 
zoster.  VOka was derived from wild-type parental Oka VZV (POka) by propagation in 
human embryonic lung cells, guinea pig embryo fibroblasts, and human fibroblasts (3, 4). 
VOka is a genetic mixture of at least 8 genotypes (5), and initially the genomes of POka 
and VOka were found to differ by 42 nucleotides and 20 amino acids (6). A recent study 
using deep sequencing identified 165 additional nucleotide changes in VOka, although 
most changes were presence in <10% of viral genomes (7). Attenuation of VOka is 
postulated to be due to mutations in multiple regions of the genome (8, 9). 
Despite numerous studies, the mechanisms for establishment and maintenance of 
VZV latency and subsequent reactivation remain poorly understood, primarily due to the 
lack of robust in vivo and in vitro models for latency. Several rodent models for VZV 
latency have been explored to date, but none has demonstrated reactivation (10). While 
simian varicella virus can establish latency and reactivation in monkeys, there are 
important differences in the simian and human varicella viral genomes and these 
experiments are limited by the cost associated with these animals (11). Human cadaveric 
ganglia have been used to study viral transcripts and proteins expressed during latency. 
While several VZV mRNAs and proteins have been detected in human ganglia (12), 
more recent studies suggest that certain prior studies of protein expression during latency 
may be due to nonspecific antibody staining (13, 14) and mRNA expression has been 
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postulated to reflect post-mortem events rather than the true latent state (15). Recent 
advances in stem cell research allow a virtually unlimited supply of human neurons 
differentiated from human embryonic stem cells (hESC) or human induced pluripotent 
stem cells (hiPSC) that have not been infected with VZV. This contrasts with the use of 
neurons from sensory or cranial nerve ganglia isolated from human cadavers, most of 
which have already been infected with VZV. Neurons from hESC fully support lytic 
infection after infection with cell-associated POka VZV of either the cell body (soma) or 
axons through retrograde transport using in compartmented microfluidic chambers (16, 
17). In this model, the cellular transcriptome in productively infected neurons is different 
from that reported for fibroblasts, T cells and keratinocytes (18-20). Recently, Markus et 
al. reported an in vitro model of latency and reactivation of VZV in hESC-derived 
neurons using a compartmented microfluidic chamber and selective axonal infection of 
POka-based recombinant virus (21). A latent infection could be established with 
expression of multiple VZV mRNAs at low levels; induction of reactivation by a 
phosphatidylinositol 3-kinase (PI3K) inhibitor period resulted in spreading of ORF66 
gene-fused GFP within a cluster of neurons. 
Here we report an in vitro system using selective axonal infection of human neurons 
derived from hESC that allows establishment and maintenance of latent VZV in which 
virus reactivation can be induced with antibody to nerve growth factor (NGF). We use 
this system to show that while VOka can establish latency with a similar efficiency as 




Cells and viruses 
Human embryonic stem cell (H9) derived neural stem cells (NSC) were cultured in 
StemPro NSC SFM complete medium consisting of KnockOut D-MEM/F-12 with 
StemPro Neural Supplement (2%), EGF (20 ng/mL), bFGF (20 ng/mL) and GlutaMAX-I 
(2 mM) as adherent cells in flasks or plates coated with CELLStart (1:100) according to 
the manufacturer’s instructions (Life Technologies, Carlsbad, CA). The use of 
commercially sourced NSC are excluded from NIH IRB review and Office of Human 
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Subjects Research Protections determination consistent with the NIH Human Research 
Protection Program.  NSC were used after 2nd to 10th passages. Neurons were 
differentiated from H9-derived NSC in neural differentiation medium consisting of 
Neurobasal medium with B-27 serum-free supplement (2%) and GlutaMAX-I (2 mM) for 
least 11 days in 12-well plates or a microfluidic device coated with CELLStart (1:100) or 
poly-D-lysine (PDL; 200 µg/mL) (Sigma-Aldrich, St. Louis, MO) and matrigel (1.25 
µg/mL) (Corning, Bedford, MA).  Human lung (MRC-5) fibroblasts were cultured in 
minimum essential media (MEM) (Life Technologies) supplemented with 10% heat 
inactivated fetal bovine serum (FBS) (Sigma-Aldrich) and GlutaMAX-I (2 mM) (Life 
Technologies). 
The VZV parental strain Oka (POka) was kindly provided by Michiaki Takahashi 
(Osaka University, Suita, Osaka, Japan) and vaccine Oka (VOka) (Zostavax) was 
purchased from Merck (Whitehouse Station, New Jersey). Viruses were propagated on 
MRC-5 cells and cell-free virus was prepared as previously described (22); cells were 
disrupted using a Misonix sonicator 3000 (Misonix, Farmingdale, NY).  
Cell-free VZV was titrated by serial 10-fold dilutions in 400 µl of culture medium 
and added to MRC-5 cells for 1 hr at 37°C, washed twice with MEM, and cultured for 7 
days.  Cells were fixed with 4% paraformaledehyde in PBS, and stained with mouse 
monoclonal anti-VZV glycoprotein E (gE) antibody (1:3,000) (clone 8612, EMD 
Millipore, Billerica, MA) followed by ECL anti-mouse IgG horseradish peroxidase-
linked whole antibody (1:3,000) (GE Healthcare Bio-Sciences, Piscataway, NJ). Plaques 
were visualized with 3, 3’, 5, 5’-tetramethylbenzidine-H (TMB-H) peroxidase substrate 
(Moss, Inc., Pasadena, MD) and counted. 
 
Microfluidic devices and neuron cultures 
A four well polydimethylsiloxane-based microfluidic device comprised of two 
compartments (length=8 mm, width=1 mm) separated by an array of 200 microchannels 
(length=500 µm, width=10 µm, height=2.5 µm) (Fig. 1) was fabricated as previously 
described (23). We previously showed that these devices allow selective growth of axons 
in one compartment, enable isolation of cell soma from their axons, and allow 
independent manipulation of somal and axonal compartments (24-26). To allow cells to 
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adhere to the device, the devices were treated with poly-D-lysine and Matrigel (Corning). 
A 200 µg/mL solution of poly-D-lysine (Sigma-Aldrich) diluted in molecular grade water 
was introduced by way of access ports, incubated overnight at 37°C in a humidified, 5% 
CO2 incubator, and the device was washed 3 times with double deionized water to 
remove unbound poly-D-lysine. The device was then coated with a 1.25 µg/mL solution 
of Matrigel diluted in KnockOut D-MEM/F-12, incubated for 2 hr at room temperature 
followed by overnight incubation at 37°C in a humidified, 5% CO2 incubator, and 
maintained at room temperature until use. 
For differentiation of NSC into neurons, 4 µl of NSC (2.5 x 107 cells/ml) were 
loaded into the somal compartment of the device in neural differentiation medium, and 20 
µl of media was added in the axonal compartment to prevent movement of NSC from the 
somal compartment to the axonal compartment. The cells were cultured for 2 hr at 37°C 
in a humidified, 5% CO2 incubator and media was added to each compartment with a 
higher medium level in the axonal compartment to prevent the movement of NSC from 
the somal compartment to the axonal compartment. Half of media was changed every 4 
days and cells were maintained until axons were observed in the axonal compartment 
(typically 21-30 days post differentiation). Differentiation into neurons was confirmed by 
neurite outgrowth and expression of beta-III tubulin as a neuron-specific marker. Neurons 
were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% Triton-X 100, 
and stained with mouse monoclonal anti-beta-III tubulin antibody (1:100) (clone 
SDL.3D10, Sigma-Aidrich) followed by Alexa Fluor 488-labeled donkey anti-mouse IgG 
antibody (1:200) (Life Technologies) and DAPI (4',6-diamidino-2-phenylindole). 
 
Immunofluorescence studies of neuron cultures 
Neuron cultures were washed with PBS, fixed for 20 min with 4% paraformaldehyde, 
washed again, and incubated in blocking solution (0.25% Triton X-100 and 5% normal 
donkey serum) for 1 hr.  Cells were stained with the following primary antibodies diluted 
in blocking solution overnight: mouse anti-β-III-tubulin (a marker for neurons; 1:1000, 
Abcam), rabbit anti-Map2 (microtubule-associated protein, a marker for neurons; 1:200, 
Sigma), mouse anti-Brn3a (a marker for sensory neurons; 1:200, Chemicon), rabbit and 
goat anti-peripherin (a marker for peripheral nervous system neurons; 1:200, Abcam and 
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1:200 Santa Cruz), rabbit anti-GFAP (glial fibrillary acid protein, a marker of cells of 
astrocyte origin; 1:1000, Dako), rabbit anti-IBA-1 (a marker for microglia; 1:500; Wako 
Chemicals), rabbit anti-Olig2 (a marker for oligodendrocytes; 1:200, Millipore), and 
mouse anti-MBP (myelin basic protein; a marker of oligodendrocytes; 1:1000, Covance).  
Cells were then washed, incubated with Alexa Fluor conjugated donkey secondary 
antibodies for 2 hr, washed, incubated for 5 min with 1 μm 4′,6-diamidino-2′-
phenylindoldihydrochloride (DAPI, Invitrogen) as a nuclear counterstain, and imaged.  
 
Virus infections 
Neurons were infected with VZV at the somal (cell body) or axonal compartments for 2 
hr at 37°C using an MOI (multiplicity of infection) based on the titer of virus obtained in 
MRC-5 cells. After 2 hr, the virus inoculum was removed, cells were washed with media, 
treated with low pH buffer (40 mM sodium citrate, 10 mM potassium chloride, 135 mM 
sodium chloride, pH 3.2) for 30 sec to inactivate virus that had not entered the cells as 
described previously (27), and neural differentiation medium was added. For virus 
reactivation, anti-nerve growth factor (NGF) antibody (AB1528SP, EMD Millipore) was 
added to the somal and axonal compartments at a final concentration of 50 µg/mL and 
cultured for 7 days. IgG isotype control antibody (Purified Sheep IgG, R&D systems, 
Minneapolis, MN) was used as negative control. Cells were fixed with 4% 
paraformaldehyde in PBS, permeabilized with 0.1% Triton-X 100, and stained with 
mouse monoclonal anti-VZV gE antibody (1:500) (clone 8612) followed by Alexa Fluor 
488-labeled donkey anti-mouse IgG antibody (1:200) and DAPI. 
 
DNA and RNA isolation, cDNA synthesis and quantitative PCR 
Total DNA and RNA were isolated from cells using an AllPrep DNA/RNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. DNA was eluted from the column 
in 100 µL elution buffer and RNA was treated with recombinant DNAse I (5 units/100 
µL) (Roche Diagnostics, Mannheim, Germany) for 1 hr at 37°C and then eluted in 30 µL 
nuclease free water. cDNA was synthesized with 10.4 µl of RNA and anchored-
oligo(dT)18 primer in a 20 µl reaction using a Transcriptor High Fidelity cDNA synthesis 
kit (Roche Diagnostics). 
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Relative quantitative PCR (qPCR) and absolute qPCR were performed using 
DNA and RNA extracted from 5 x 104 cells per reaction.  1 µl of DNA (representing 1% 
of the total DNA extracted) or 1 µl cDNA (obtained from 3.3% of the total RNA 
extracted) were used in a 15 µl reaction in duplicate with FastStart Universal SYBR 
Green Master (Rox) (Roche Diagnostics) in a 7500 Real-Time PCR System (Life 
Technologies). The qPCR program was 1 cycle of 95°C hot start for 10 min and 45 
cycles of 95°C for 15 sec and 60°C for 45 sec. For relative qPCR, primers for CD24 were 
used as a DNA internal control, and primers for beta-actin to amplify cDNA were used as 
an RNA) internal control. VZV genomic DNA was quantified by amplification of ORF61 
for relative qPCR.  For absolute qPCR, a standard curve was generated using 10-fold 
serial dilutions of known copy number (106 to 1) of VZV POka BAC genome (VZVLuc 
BAC, a kind gift from Hua Zhu, UMDNJ-New Jersey Medical School, Newark, NJ) (28). 
A dissociation curve analysis from 60°C to 95°C was performed after every qPCR run to 
exclude primer-dimer formation and other non-specific amplification. Viral mRNA was 
detected by amplification of cDNAs from immediate-early genes ORF62 and ORF63, a 
putative immediate-early gene ORF61, a putative early gene ORF16, and putative late 
gene ORF42/45. Primer sequences are listed in Table S1. 
 
VZV DNA configuration 
VZV DNA configuration was determined by the ratio of genomes with fused termini to 
linear genomes (29) with slight modifications. The copy number of fused termini was 
determined by qPCR using primers T1 and T2, and the copy number of linear genomes 
was quantified by using primers to ORF49 (ORF49F21 and R80; Fig. 2A). A standard 
curve for circular genomes was generated using VZVLuc BAC. The qPCR conditions 
were 1 cycle of 95°C hot start for 10 min and 45 cycles of 95°C for 15 sec, 58°C for 10 
sec, and 72°C for 45 sec.  
 
RNA Library Construction and Sequencing 
Stranded mRNA-Seq libraries were constructed with a SureSelect Strand Specific RNA 
Library kit (Agilent Technologies, Santa Clara, CA) using polyA-selected mRNA 
extracted from two independent neuronal cultures containing latent POka VZV. 200ng of 
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total RNA was used as input. Samples were multiplexed and sequenced using a NextSeq 
550 using a 75 cycle V2 kit, producing 36.8 and 41.2 million 2 x 33 bp paired end reads 
per sample. 
 
RNA Seq analysis 
Quality control was performed by assessing various metrics (read duplication, transcript 
integrity scores, read distribution and gene body coverage) using RSeQC (30). Paired-end 
reads were trimmed (Trim Galore – 
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/)) and aligned against 
the Homo sapiens genome (HG19 assembly) using Tophat (31) to reduce the dataset. 
Unmapped read-pairs were subsequently aligned against POka using Tophat and FPKM 
values determined using cufflinks (32). BAM files were processed using SAMtools (33) 
and custom R scripts to produce maps of read coverage and depth across both strands of 
the VZV genome.  
 
DNA Library Construction, Targeted Enrichment, and Sequencing 
Sequence libraries were constructed and hybridized with custom designed VZV-specific 
120-mer RNA oligonucleotides as described previously (7), the only modification being 
the use of 200ng of starting DNA, as described in the SureSelect XT v1.6 protocol 
(Agilent Technologies). Sequencing libraries were multiplexed and sequenced on a single 
Illumina MiSeq run (500bp V2 kit) yielding ~25,000,000 paired-end reads. 
 
Genome Assembly and Variant Calling 
Following demultiplexing, each sequence data set was profiled using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and parsed through QUASR 
(34) and Trim Galore for duplicate removal and read-trimming, respectively. Sequence 
reads were aligned against the VZV reference strain POka (AB097933) using Burrows-
Wheeler Alignment (35). Resulting alignments were processed using SAMtools (33) to 
generate pileup files for each sample. A consensus sequence for each data set was called 
with the QUASR module pileupConsensus at an 80% frequency threshold (i.e. 
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ambiguities were included if the variant frequency lay between 20-80%). Variant 
profiling for each data set was performed using VarScan v2.2.11 (36) with the following 
parameters: base call quality ≥20, read depth ≥50, independent reads supporting minor 
allele ≥2 per strand. In addition, variant calls showing directional strand bias ≥0.85 were 
excluded from further analyses. Prior to any analysis the iterative repeat regions (R1, R2, 
R3, R4, and R5) and the terminal repeat region were masked. 
 
Consensus Sequence and Variant Analyses 
Consensus sequences were aligned using MAFFT (37) and resulting alignments visually 
corrected using Mega v6 (38). Custom PERL scripts were used to profile differences 
between consensus sequences. For variant analyses, frequency plots were generated using 
custom R scripts. 
 
Population complexity analysis using entropy 
Entropy is a measure of the diversity within a sample, with greater entropy indicating 
greater diversity. The formula for calculating the entropy of a position is:           






)𝑆𝑖−1  where Fi is the frequency of nucleotide i, T is the total 
number of nucleotides at the position and base b=2 for the logarithm). The entropy is 
calculated for each nucleotide with the entropy of each of the 4 nucleotides being 
summed to give the entropy of a position. Rare variants do not contribute much to the 
entropy as the log of their proportion will be very close to 0. The entropy of each position 
was calculated and then the entropy of each position was summed to give the entropy of 
the sample. 
 
Kolmogorov-Smirnov Test (KS-test)  
The KS-Test is used to determine if two datasets differ significantly without making any 
assumptions about the distribution of data. Here, two samples are plotted together in 
cumulative form, and each is scaled so their cumulative sums are 1.0. The Kolmogorov-
Smirnov statistic (D) reflects the greatest distance between the two. Critical values for the 
D statistic were determined by the number (N) of sites compared and was calculated as 
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1.36/(√N) for p = 0.05. The null hypothesis (both sets of data are drawn from the same 




VZV infection of the soma of human neurons usually induces a productive infection, 
while infection of axons or very low titer infection of soma results in persistent 
infection. 
Human neural stem cells (NSC) were plated in the soma compartment of a microfluidic 
device (Fig. 1A, left panel).  Human neurons were obtained by differentiating neural 
stem cells (NSC), derived from human embryonic stem cells (H9). Outgrowth of neurites 
was visible 3 days after differentiation of NSC into neurons in the somal compartment 
and 5 to 7 days in the axonal compartment. At 21 to 30 days after differentiation, axons 
were abundant in the axonal compartment and beta-III tubulin, a marker for neurons, was 
detected in >99% of the cells (Fig. 1A right panels).  Less than 1% of the cells stained 
with antibodies for astrocytes and none of the cells stained with microglia or 
oligodendrocyte markers.  Approximately 5% of the cells expressed peripherin and 
Brn3a, consistent with sensory neurons.   
Neurons are highly permissive for infection with POka VZV, the parental virus of 
the live attenuated VZV Oka vaccine strain (VOka), when the cells are grown in vitro. 
While neurons grown in typical cell cultures are infected with VZV at both the soma and 
axon simultaneously, neurons grown in microfluidic devices can be selectively infected 
either at the somal compartment, where neuronal cell bodies, axons, and dendrites reside, 
or the axonal compartment, where the only distal axons and axon terminals reside. VZV 
POka cell-free virus (2 x 104 pfu/ml titrated on MRC-5 cells) was serially diluted (10-fold 
dilutions) from 0.5 µl (10 pfu on MRC-5 cells) to 0.0005 µl (0.01 pfu on MRC-5 cells) 
and neurons were infected at the soma. At 8 days post infection, 0.5 to 0.005 µl of cell-
free virus induced lytic infection and expressed abundant glycoprotein E (gE) in neurons, 
while 0.0005 µl of cell-free virus did not result in gE expression (Fig. 1B). VZV DNA 
replication and gene expression were analyzed by qPCR using DNA and reverse-
transcriptase (RT)-qPCR using RNA, respectively (Fig.1C). The quantity of VZV DNA 
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in neurons increased at 8 days after somal infection with increasing amounts of virus 
from 0.0005 to 0.5 µl (Fig. 1C, left panel, rows 1, 3, 5 and 7) or at 14 days after 
infection with 0.0005 to 0.005 µl of virus (Fig. 1C, left panel, rows 2 and 4), while the 
level plateaued 14 days after infection in neurons infected with 0.05 and 0.5 µl of virus 
(Fig.1C, left panel, row 6 and 8). Genes from each of the kinetic classes of VZV, 
including ORF62 and ORF63 (immediate-early genes), ORF61 (putative immediate-early 
gene), ORF16 (putative early gene encoding a subunit of the viral DNA polymerase) and 
ORF42/45 (putative spliced late gene) were detected by RT-qPCR in neurons infected at 
the soma with 0.005 to 0.5 µl of cell-free virus (Fig. 1C, right panel, rows 3 to 8). In 
contrast, while VZV DNA was present at days 8 and 14 after infection with a very low 
amount (0.0005 µl) of cell-free virus, no viral gene expression was detected (Fig. 1C, 
rows 1 and 2), suggesting that low titer virus can infect neurons, but not result in 
detectable VZV gene expression or lytic replication. Additional experiments using 0.0005 
µl of cell-free virus to infect the somal compartment showed persistence of viral DNA, 
but absence of detectable VZV gene expression even at 70 days after infection. This 
suggests that the cells may have been latently infected. However, we could not exclude 
the possibility that (a) cell-free virus persisted on the cell membrane without infecting the 
cell and/or (b) free viral DNA present in the inoculum persists bound to the cell. The 
instability of cell-free virus produced in cell culture, the repeated washes after infection 
(including with low pH solution immediately after infection), and the long time between 
infection and assays for DNA and RNA (up to 70 days) all favor latent infection without 
gene expression. 
To provide further evidence for latent infection of neurons in vitro, and to mimic 
what may occur in vivo, axons of neurons were infected with VZV POka in the 
microfluidic device using different doses of cell-free virus. The media level was kept at 
least 7-fold higher in the somal compartment than the axonal compartment of the device 
throughout the infection, including initial inoculation, washing steps, incubations, and 
changes of media to induce a hydrostatic pressure gradient which prevents inoculum from 
diffusing from the axonal compartment to somal compartment (24-26), but does not 
prevent virus from being transported to the soma through axons. To our surprise, even 
when using the highest dose of VZV that could be applied to the axonal compartment (5 
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µl of cell-free virus + 5 µl of media), neuronal cell bodies on the somal compartment did 
not show any expression of gE or CPE at 8 dpi (Fig. 1B, right panel), and no viral 
mRNA, including ORF63, was detected by RT-qPCR; however, VZV DNA was 
detectable by qPCR at 8 and 14 dpi (Fig. 1C, rows 9 and 10, respectively). VZV DNA 
was detected in the soma at 2 hours after infection at the axonal compartment and its 
persistence in the absence of detecting VZV mRNA was observed up to 70 days after 
infection, suggesting that selective axonal infection of VZV in the microfluidic device 
results in persistent infection and may mimic latent infection which occurs in in human 
ganglia.  Axonal infection may be a relatively inefficient method to deliver VZV to the 
soma, relative to direct soma infection, and persistent infection might be favored over 
lytic infection simply by a very low quantity of VZV genomes in the soma. 
While no VZV RNA was detected by qPCR, deep sequencing using stranded 
RNA-seq of two independent POka-infected neuronal cultures after selective axonal 
infection for 14 dpi showed variable, but low levels of transcription across all VZV ORFs 
(Fig. 1D). The pattern of VZV gene expression was consistent between both cultures and 
shared many characteristics with quiescent VZV obtained from neuronal cultures using a 
different system (21).   
 
The VZV genome in human neurons infected at the axonal compartment is 
maintained with fused VZV genomic termini consistent with an episomal 
configuration. 
In human trigeminal ganglia latently infected with VZV, the viral DNA persists with 
fused termini likely in a circular configuration (29). This observation is based on a ratio 
of terminal to internal DNA obtained by PCR reactions of 1 (1:1) for VZV DNA from 
latently infected ganglia compared with a ratio of 0.067 (1:15) for VZV DNA in virions. 
Cells undergoing lytic replication would be expected to have an intermediate ratio since 
they contain a mixture of virions and circular VZV DNA during rolling circular 
replication. If axonal infection of neurons with VZV in the microfluidic device mimics 
latency, the ratio of internal to terminal DNA should be 1.   
The ratio of fused terminal DNA (using primers T1 and T2) to internal DNA 
(using primers that detect ORF49) (Fig. 2A) was determined for the VZVLuc BAC, which 
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is a circular form of the genome, was set as one (Fig. 2B, lane 1). The ratio of fused 
terminal DNA to internal DNA for POka isolated from virions was 0.012 ± 0.001 
indicating that it contains linear unit length genomes without fused termini with little or 
no intracellular circular, replicating VZV DNA (Fig. 2B, lane 2). In lytically infected 
neurons at 14 dpi, the ratio was 0.430 ± 0.0341 (Fig. 2B, lane 3). In neurons infected 
with POka by the axonal route, the ratio was 1.11 ± 0.257 at 14 dpi (Fig. 2B, lane 4), 
while in neurons infected with a very low MOI (10-7) by the soma route the ratio was 
0.959 ± 0.0739 (Fig. 2B, lane 5). These data indicate that neurons persistently infected in 
vitro by the axonal route with VZV and without detectable expression of viral mRNA by 
RT-PCR harbor the genome with fused termini, likely in a circular or an episomal 
genome, similar to that seen in latently infected human ganglia.  
 
Treatment of persistently infected neurons with antibody to nerve growth factor 
induces VZV genome replication, expression of viral mRNA, and production of 
infectious virus  
Latently infected cells have an intact viral genome that has the ability to reactivate and 
produce infectious virus. Therefore, we treated persistently infected neurons with several 
compounds known to reactivate other herpesviruses. These included histone deacetylase 
(HDAC) inhibitors, such as butyric acid (8 mM), hexametylene bisacetamide (10 mM), 
and valproic acid (5 mM) which have been shown to reactivate HSV and EBV (39) or a 
STAT3 inhibitor (10 mM S3I-201) or anti-nerve growth factor (NGF) antibody which 
reactivates HSV (40-42). In neurons infected by the somal route with low dose cell-free 
POka VZV or at the axonal compartment in microfluidic devices with high dose cell-free 
virus, reactivation was not induced by treatment with HDAC or STAT3 inhibitors; 
however, treatment of neurons infected with POka by the axonal route with anti-NGF 
antibody (50 µg/ml) did induce VZV reactivation. At 14 days after axonal infection of 
neurons with 5 µl of POka cell-free VZV in a microfluidic device, there was no CPE and 
viral mRNA was not detected by RT-PCR; however, viral DNA was present. Seven days 
after adding anti-NGF antibody, some cells showed CPE in the microfluidic device.  
Cells were removed from the device and one aliquot was used to isolate DNA and RNA. 
Viral DNA was increased after reactivation and immediate-early, putative early, and 
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putative late VZV genes were detected by qPCR in some (Fig. 3A, row 3), but not all 
(Fig. 3A, row 1 and 5) somal compartments. The other aliquot of cells was treated with 
trypsin and used to infect MRC-5 cells.  CPE and VZV gE expression were present in 
MRC-5 cells after 2 to 3 days, but only in the same compartments in which the neurons 
showed accumulation of VZV DNA and viral gene expression (Fig. 3B, lower right 
well). This indicated that anti-NGF antibody was able to reactivate the viral genome, 
resulting in production of infectious virus. In the absence of anti-NGF antibody, no 
amplification of the viral genome was detected by qPCR, no detection of viral mRNA 
was found by RT-PCR (Fig. 3A, rows 2, 4 and 6), and no infectious virus or gE 
expression was present after transfer of neurons to MRC-5 cells (Fig. 3B, upper wells). 
In four independent experiments, reactivation rates ranged from 17% to 33% with a mean 
of 27% after addition of anti-NGF antibody, while reactivation never occurred in the 
absence of the antibody or with addition of IgG isotype control antibody (Table 1). 
MRC-5 cells, which showed CPE after infection with the anti-NGF antibody treated 
neurons, were passaged onto uninfected MRC-5 cells and CPE and VZV gE was noted in 
the latter cells 7 days after infection (Fig. 3C). In summary, since infectious VZV was 
produced from persistently infected neurons only after treatment with anti-NGF antibody, 
these infected neurons meet the criterion for latency. 
 
VOka, like POka can establish latency in neurons in vitro, but is impaired for 
reactivation. 
The Oka vaccine virus  (VOka) (3, 4) results in lower rates of zoster when compared with 
wild-type virus in healthy and immunocompromised children (43-46). At present, it is 
unknown whether the vaccine virus is impaired for establishment of latency, for 
reactivation, or both. Therefore, we compared the ability of POka and VOka to establish 
latency and reactivate in our in vitro latency model. Neurons were infected at the axonal 
compartment with an equal number of PFU (40 pfu) of cell-free POka and VOka. At 14 
days after axonal infection, neurons infected with either virus showed no CPE and no 
viral mRNA was detected by RT-qPCR (Fig. 4A, right panel); however, the VZV 
genomic DNA copy number in neurons was similar (Fig. 4A, left panel).  In neurons 
infected with VOka by the axonal route, the ratio of fused terminal DNA to internal DNA   
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was 0.965 ± 0.135, indicating that VOka, like POka (Fig. 2B, lane 4) likely has a circular 
genome.   
To compare the rate of reactivation of neurons infected with POka and VOka, 
anti-NGF antibody was added to the cells for 7 days, after which the neurons were 
removed and plated onto MRC-5 cells, and 7 days later plaques were visualized and 
confirmed with anti-gE antibody (Fig. 4B). In four independent experiments (n = 39), the 
mean rate of reactivation was 23.1% for POka, compared with 5.1% for VOka (Table 2) 
(p = 0.012; student-t test, two tailed). These experiments imply that VOka can establish 
latency at a similar rate to POka, but that VOka is significantly impaired for reactivation 
compared to POka in vitro.  While it is possible that the reduced level of reactivation of 
VOka compared to POka was solely be due the slightly reduced DNA copy number of 
VOka in latently infected neurons, this seems unlikely since the difference in the level of 
latent VOka and POka latent DNA was modest and not statistically significant (p = 
0.987, student-t test, two tailed). 
Deep sequencing using stranded RNA-seq of VOka-infected neuronal cultures 
after selective axonal infection for 14 dpi showed little or no transcription across VZV 
ORFs (Fig.1E), which markedly differed from the pattern of transcription with POka-
infected neurons (Fig. 1D). (Note that the scale of the peaks in the inner two circles for 
POka is 1000-fold higher than the scale for VOka). 
Comparative analysis of neuronal transcripts obtained from POka- and VOka-
infected cultures revealed just 8 differentially expressed genes, four of which are 
characterized (CLEC4A, EGR1, CYR61 and SEMA3D) while two remain 
uncharacterized and two are annotated as pseudogenes (Table S2). 
 
VOka undergoes a loss in heterogeneity during reactivation in vitro, but not during 
latency  
Nine sequencing libraries were enriched for POka (N = 4) and VOka (N = 5) DNA using 
SureSelect (7) that had sufficient reads to generate high confidence genome assemblies 
where > 99.9% of the genome was covered at read depths exceeding 50x (Table S3). 
VarScan (36) was used to report all sites at which a variant allele was present, either 
fixed or mixed with the reference allele. We compared variant allele frequencies between 
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the input POka population and the latent POka population after 14 days (samples were 
from separate aliquots described in figure 4). We identified 42 sites with variant alleles, 
across the genome, 35 of which were present in both the input and latent POka 
population.  Of these, 31 differed in allele frequency by less than 15% (mean = 6.5%) 
between input and latent POka. Seven new mutations [i.e. not present in the input pOka 
(P1)], were present in latent POka, all at frequencies below 10% (Figure S1). Variant 
alleles at nucleotides 58914 (ORF31, Q699R), 106262 (ORF62, R958G) and 109281 plus 
110057 (both in the non-coding region between ORFs 62 and 63) increased by 17-42% in 
latent POka while the variant at nucleotide 58914 (ORF31, R699), increased from 48% in 
the input pOka to 90% in the latent populations.  There was no significant difference in 
the SNP frequencies between input and latent POka samples (KS Test D = 0.23, p = 
0.08). Using entropy as a measure of population complexity, we observed only a very 
slight gain in heterogeneity between input (S = 12.52) and latent (S = 13.58 - 16.39) 
POka samples after 14 days (Fig. 5A).  
Next, we compared variant allele frequencies between the input VOka population, 
the latent VOka population at 14 days after axonal infection, and the reactivated 
population 7 days after adding anti-NGF antibody (samples were from separate aliquots 
described in figure 4). We identified 195 polymorphic loci in the input genome, 143-160 
in the latent samples, and 128-173 in the reactivated samples. Only a single site (100114, 
ORF58, K53N) was significantly changed between the input (36.69%) and the latent and 
reactivated samples (mean = 98.96%) (Figure S2). Similarly, only a single variant allele 
(position 2493, non-coding, input = 6.63%) was consistently absent in the latent and 
reactivated samples. The viral population structures showed statistically significant 
changes between all three states (KS-Test; input vs. latent, D = 0.2826, p < 0.01; latent 
vs. reactivated, D = 0.3000, p < 0.01; input vs. reactivated, D = 0.3000, p < 0.01). 
However, the diversity and complexity (entropy), although similar for the input (S = 
71.79) and latent (S = 69.99-87.19) VOka, were markedly higher than that for reactivated 
virus (S = 17.05-26.2) (Fig. 5B). Thus, infection of neurons with VOka resulted in a loss 





We have established an in vitro system for VZV latency and reactivation by selective 
infection of human neuronal axons with cell-free virus. We found that (a) VZV enters 
neurons without detectable viral gene expression by RT-qPCR or lytic replication, (b) the 
VZV genome is maintained with fused termini indicative of an episomal configuration, 
and (c) VZV can reactivate from neurons by the addition of anti-NGF antibody. 
Furthermore, comparison of infection of VOka and POka in our system showed that 
VOka can establish latency at a similar rate to POka, but VOka is impaired for 
reactivation. Neurons latently infected with VOka showed markedly reduced viral 
transcription based on deep sequencing using stranded RNA-seq compared with neurons 
latently infected with POka. 
 We found that axonal infection of neurons with cell-free virus resulted in a latent 
infection. In contrast, when we tested neurons by simultaneously infecting both the soma 
and axon using cell-free POka, we observed lytic infection leading to cell death, even at 
extremely low titers of virus (Fig. 1B). VZV infection of neurons has been postulated to 
occur either by retrograde axonal transport from cutaneous lesions or by hematogenous 
transfer of VZV to neurons in human ganglia during varicella. Evidence for infection 
from the bloodstream includes both animal models and clinical observations. Intravenous 
infection of VZV-infected human tonsil T cells can transfer VZV to neurons in human 
fetal ganglia xenografts in SCID (severe combined immunodeficiency)-hu mice (47). In 
humans, multiple sensory ganglia (48) as well as enteric ganglia (1) are latently infected, 
consistent with viremic spread, since enteric ganglia do not project to the skin. There is 
also extensive clinical evidence for retrograde axonal transport of virus from infected 
epidermal or dermal cells to neurons in sensory ganglia. Herpes zoster occurs most 
frequently on the face and upper thorax which is the area most severely affected by 
varicella (48, 49). Herpes zoster associated with varicella vaccine is most common at the 
site of the vaccine inoculation (43) and about 50% of zoster cases associated with 
vaccination are due to wild-type virus (50). Also, VZV has previously been shown to 
enter neurons in vitro from nerve endings by cell-to-cell contact with infected cells or 
cell-free virus followed by transaxonal transport to the soma (16, 17, 21).  
While we were able to obtain latent infection of neurons using axonal infection in 
microfluidic device, other studies reported a lytic infection using this route (16, 17). 
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These studies differed from ours in that they used cell-associated virus, while we used 
cell-free virus. Markus et al. described two in vitro models of latency and reactivation of 
VZV in hESC-derived neurons (21). In the first model, human neurons were infected at 
the somal site (in the absence of a microfluidic device) using low-dose cell-free POka-
based GFP recombinant virus in the presence of acyclovir. A non-productive, persistent 
infection was observed in which viral DNA and transcripts for IE63 and ORF31 (a 
putative late gene) were detected by qPCR, and transcripts from all genomic regions were 
detected by RNA-seq analysis. Reactivation could be induced by removal of acyclovir 
and replacing the media with new media lacking three neurotrophin growth factors (NGF, 
BDNF and NT3) that had been present or by adding a PI3K inhibitor or sodium butyrate. 
In the second model, neurons were infected with VZVORF66GFP recombinant virus in 
the axonal compartment of a microfluidic chamber in the absence of acyclovir. Both 
VZV DNA and transcripts for IE63 and ORF31 were detected two weeks after infection 
by PCR, but RNA-seq analysis was not performed; treatment of the cells with a PI3K 
inhibitor resulted in increased VZV DNA and RNA expression and, after reducing the 
temperature to 34°C, GFP expression was detected in a few cells. Our system differs 
from the second model (21), which also used a microfluidic device, in several respects.  
First, we used POka, a non-recombinant virus, which should be very similar to virus 
isolated from patients. Second, we could not detect VZV mRNAs during latency 
including immediate-early (ORF61, ORF62, ORF63), putative early (ORF16), and 
putative late (ORF42/45) genes by RT-qPCR using an assay which detects less than 10 
copies of mRNA per reaction. Third, we demonstrated that virus could be passaged to a 
new cell type. Fourth, our experiments were performed at 37°C, and we did not need to 
reduce the temperature to 34°C to observe full evidence of reactivation. Fifth, we induced 
reactivation by adding anti-NGF antibody; in fact, we could not reactivate virus using a 
PI3K inhibitor.  
We found that axonal infection with cell-free virus resulted in latent infection 
without detectable viral gene expression by RT-qPCR. VZV latency has been defined 
using human cadaveric ganglia, because of a lack of in vitro or in vivo models that 
reproduce both latency and reactivation.  While multiple viral proteins have been 
detected by immunohistochemistry in human cadaveric ganglia [reviewed in (52)], recent 
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studies showed that anti-VZV mouse monoclonal antibodies obtained from ascites and 
anti-VZV rabbit polyclonal antibodies contain antibodies to human blood group A1-
associated antigens (13, 14) which casts doubt on the presence of VZV proteins during 
latency in human ganglia in some prior reports (2). Initial studies of VZV transcription in 
human ganglia used tissues obtained at various times post-mortem and using a variety of 
techniques multiple transcripts were detected [reviewed in (52)]. More recent studies 
suggest that transcription of VZV during latency in human ganglia may be more limited. 
When human ganglia were obtained less than 9 hours post-mortem, no VZV RNAs could 
be detected by multiplex RT-PCR, and only ORF63 mRNA could be detected by RT-
qPCR (15). In contrast, multiple VZV mRNAs were detected when ganglia were obtained 
9 hours or more post-mortem and higher levels of ORF63 mRNA were also seen later 
post-mortem. These results suggest that detection of multiple VZV mRNAs in human 
cadaveric ganglia may reflect reactivation post-mortem, rather than true latent infection.  
Studies of ganglia obtained from the intestines of children soon after surgical excision, 
who had a history of varicella, showed ORF63 mRNA in 83% of specimens followed by 
ORF4 in 67% (1). At present, it remains controversial as to which VZV proteins and 
transcripts are expressed during VZV latency in vivo [reviewed in (51)].  VZV latency 
may be similar to HSV with most latently infected cells expressing no viral mRNAs or 
proteins (53). Thus, the inability to detect VZV transcripts by RT-qPCR in our in vitro 
model of VZV latency may reflect the state of latency in human ganglia during life. 
However, we found that RNA-seq analysis detected transcripts for all annotated genes 
during latency in vitro. Whether these low level transcripts are functional or not is 
unclear. We are not aware of any published studies using RNA-seq and VZV or HSV 
latently infected human ganglia, so it is unclear if low levels of viral transcripts are 
present in these tissues. However, RNA-seq analysis of latent EBV Burkitt lymphoma 
cells shows transcription across the viral genome (52). 
The in vitro latency system that we describe differs from latently infected sensory 
ganglia in several aspects.  More than 99% of the cells we infected expressed neuronal 
markers; therefore, our system contains few if any of the other cell types present in 
sensory ganglia such as satellite cells, fibroblasts, and immune cells (e.g. macrophages 
and lymphocytes).  Thus, many cell-cell interactions and soluble factors secreted by non-
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neuronal cells that are present in sensory ganglia are absent in our system. It is possible 
that the absence of detectable VZV gene expression by RT-PCR in our system may be 
due to the lack of non-neuronal cells that could influence viral gene expression in 
neurons.  In addition, only ~5% of the neurons in our system expressed markers of 
sensory neurons, indicating that there was a heterogeneous population of neurons present.  
Thus, the composition of neurons in our system differs from that in sensory ganglia.   
We found that the VZV genome maintained in human neurons had fused VZV 
genomic termini consistent with an episomal configuration. A prior study with latently 
infected human ganglia showed that the viral genome had fused termini likely from a 
circular or concatemeric configuration (29). Herpesvirus genomes are present in a unit 
length linear configuration within nucleocapsids and quickly circularize after entering the 
nucleus (53). Long head-to-tail concatemers of viral DNA are produced by rolling circle 
DNA replication by viral DNA replication proteins (53). Our in vitro model of VZV 
latency in the absence of gene expression by RT-qPCR suggests that the VZV genome 
exists as a circular configuration rather than as concatemers. 
We showed that treatment of latently infected neurons with neutralizing antibody 
to NGF induced VZV genome replication and expression of viral mRNA with production 
of infectious virus. An in vitro model of HSV latency was developed in which HSV-1-
infected neurons from neonatal rat cervical ganglia are incubated with NGF; acyclovir is 
required to maintain latency in this system (40). Treatment of the virus-infected neurons 
with anti-NGF antibody resulted in HSV-1 reactivation. The molecular mechanisms for 
reactivation of VZV resulting in herpes zoster is less clear, but trauma (53) and 
neurosurgical procedures (54, 55) have been associated with zoster. Retrograde NGF 
signaling from the axon to the soma is critical for maintenance and survival of sensory 
and sympathetic neurons (56, 57). Therefore axonal injury by trauma or neurosurgical 
procedures might reduce NGF signaling not only by interrupting retrograde transport, but 
also by altering mRNA transcription and translation (58). The ability of VZV to 
reactivate by inhibiting NGF in our in vitro system may mimic what occurs during axonal 
injury in vivo.  
VOka establishes latency after vaccination and the virus can reactivate (1, 59). 
The rate of herpes zoster is lower after vaccination with VOka compared with natural 
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infection (43-46), implying that the vaccine virus is attenuated for latency and/or 
reactivation. We found that VOka can establish latency at a similar rate with POka, but is 
significantly impaired for reactivation from latency in vitro. However, there was 
markedly reduced viral transcription during latency in neurons infected with vOka 
compared with POka. This suggests that extensive viral transcription was not required to 
maintain latency. Deep sequencing showed that VOka undergoes a loss in heterogeneity 
during reactivation in vitro, but not during latency. This loss in heterogeneity could be 
due to a selection for specific viral genotypes or a stochastic process related to the low 
numbers of sequences recovered during reactivation. The latter hypothesis may be more 
likely, since a study of rashes in persons receiving Oka vaccine virus showed that 
genotypes in rashes after vaccination or due to reactivation from latency were similar (7).  
The in vitro model of VZV latency and reactivation we report might be used to 
study the mechanism of VZV latency and reactivation and to screen for inhibitors of 
reactivation or molecules that might reduce the number of latently infected neurons. 
Furthermore, this system may also be used to study candidate viral vaccines for their 
ability to establish latency and reactivate.   
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FIGURE LEGENDS 
Figure 1. Somal infection of human neurons with VZV usually induces productive 
infection, but axonal infection results in persistent infection. (A) Human ES cell (H9)-
derived neural stem cells were seeded in the somal compartment (1 x 105 cells/sector) of 
a microfluidic device and differentiated into neurons for 21 to 30 days until abundant 
neurite outgrowth was observed in the axonal compartment. Neurons were stained with 
anti-beta III tubulin antibody and DAPI. Scale bar; 100 µm. (B and C) Neurons were 
infected with wild-type POka VZV cell-free virus at the indicated MOI in the somal or 
axonal compartment of the microfluidic device. (B) At 8 days after infection, cells were 
stained with VZV anti-gE antibody and DAPI. Scale bar; 50 µm. (C) At 8 and 14 days 
after infection, DNA and RNA were extracted from the infected cells, cDNA was 
synthesized from RNA and quantitative RT-PCR was performed.  (C, left panel) The 
relative quantity of VZV DNA (using VZV ORF61 primers) to cellular genomic DNA 
(using CD24 gene primers) is shown based on axonal infection at 8 days after infection. 
28 
 
(C, right panel) VZV mRNAs from different kinetic classes were analyzed; ORF62 and 
ORF63 immediate-early (IE) and ORF61 putative-immediate early genes, ORF16 a 
putative early gene (E), and ORF42/45 a putative late gene (L).  + indicates detected, - 
indicates not detected. (D, E) Circos plot shows VZV POka (D) and VOka (E) mRNA 
expression in neurons 14 days after selective axonal infection. The outer track contains 
the VZV genome in its prototypic orientation. The blue and green tracks show the mean 
read depth in non-overlapping 25bp windows for the stranded RNA-Seq library from two 
independent experiments (blue track performed in duplicate and green track in triplicate) 
and are analogous to gene expression. The peaks facing outward from the center indicate 
genes expressed on the positive strand while the peaks facing inward indicate genes 
expressed on the negative strand. The y axis for the peaks are the number of reads from 
mRNAseq scaled from 0 to 15,000 for POka, and from 0 to 15 for VOka. 
Figure 2. The VZV genome is maintained in axonal infected neurons with fused 
VZV genomic termini suggesting a circular or episomal configuration. (A) Map of 
the POka strain VZV genome and primers (T1, 2) used to detect fused genomic termini 
and primers (ORF49F21, ORF49R80) used to detect the internal region of the genome. 
The genome contains unique long (UL), unique short (US), internal repeat (IR), and 
terminal repeat (TR) regions. (B) Neurons were infected with POka VZV cell-free virus 
with the indicated amount of virus aliquot (with MOI based on the virus titer measured in 
MRC-5 cells) in the somal or axonal compartment of the microfluidic device. At 
indicated time points, DNA was extracted from the cells and qPCR was performed. Full 
length VZVLuc BAC in which the viral genomic termini are fused, was used as a control 
for episomal (circular) viral DNA, and VZV cell-free virus DNA was a control for linear 
viral DNA without fused termini. The ratio of the absolute copy number of PCR products 
using VZV termini primers to VZV internal primers was calculated. Absolute copy 
number was determined based on standard curves derived from 1 to 106 copies of unit-
length circular VZV-BAC DNA. The amplification efficiency of the qPCR reaction was 
calculated based on the slope of the standard curves and was 1.88 - 2.11 for ORF49 and 
1.28 - 1.33 for TR joint. 
29 
 
Figure 3. Anti-NGF antibody induces VZV genome replication, mRNA expression, 
and production of infectious virus from neurons harboring persistent infection with 
fused VZV genomic termini. Neurons were infected with cell-free VZV at an MOI of 
0.001 (titrated on MRC-5 cells) in the axonal compartment of microfluidic devices. At 14 
days after infection, anti-nerve growth factor (NGF) sheep antibody (50 µg/mL), no 
antibody, or sheep IgG isotype control antibody (50 µg/mL) was added to the somal and 
axonal compartment. After 7 days, cells were removed from the device and divided into 
two equal fractions. (A) The relative quantity of VZV genomic DNA to cellular genomic 
DNA, and detection of VZV mRNAs, was determined as described in the legend to 
Figure 1. (B and C) The other cell fraction was treated with trypsin and used to infect 
MRC-5 cells in duplicate. At 7 days after infection, cells were fixed (B) or treated with 
trypsin and passaged onto uninfected MRC-5 cells and cultured for an additional 7 days 
(C). Cells were stained with VZV anti-gE antibody.  
Figure 4. VOka establishes latency at a similar rate to POka, but is impaired for 
reactivation in vitro. Neurons were infected with cell-free POka or VOka at an MOI of 
0.001 (titrated on MRC-5 cells) in the axonal compartment of a microfluidic device. (A) 
At 14 days after infection, DNA and RNA were extracted from 4 sectors each and 
quantitative RT-PCR was performed. VZV genome DNA copy number and detection of 
VZV mRNAs were determined as described in the legend to Figure 1. (B) At 14 days 
after infection, reactivation was induced as described in the legend to Figure 3. After 
another 7 days, neurons were plated onto MRC-5 cells and cultured for 7 days. Viral 
plaques were visualized as described in the legend to Figure 3C. 
Figure 5. VOka maintains its heterogeneity during latency, but not during 
reactivation in vitro. Whole genome sequencing analyses were performed for POka (A) 
and VOka (B), and their complexity was determined by analyzing the number of sites 
undergoing nucleotide changes and calculating the entropy (S). (A) POka DNA was 
extracted from input cell-free virus (a) and from different aliquots of latent viral DNA (b 
to d) at 14 dpi (in Fig. 4). (B) VOka DNA was extracted from input cell-free virus (a), 
different aliquots of latent viral DNA at 14 dpi (b and c) and reactivated (d and e) viral 
DNA at 7 days (before adding to MRC-5 cells in Fig. 4). Frequency histograms denote 
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the frequency distribution of variant alleles. Data are binned at 2% intervals along the x-
axis and the numbers of variant sites in each bin are shown on the y-axis. Entropy (S), 
analogous to population diversity, was determined for each individual sample. 
